UroGen Pharma (NASDAQ:URGN) PT Raised to $60.00

UroGen Pharma (NASDAQ:URGN) had its price objective lifted by equities researchers at HC Wainwright from $54.00 to $60.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target suggests a potential upside of 212.50% from the company’s current price.

Separately, Oppenheimer reduced their price target on shares of UroGen Pharma from $34.00 to $32.00 and set an “outperform” rating for the company in a report on Tuesday, May 14th.

UroGen Pharma Trading Up 9.7 %

Shares of UroGen Pharma stock opened at $19.20 on Friday. The business has a 50-day moving average price of $13.76 and a two-hundred day moving average price of $15.03. UroGen Pharma has a 1-year low of $8.69 and a 1-year high of $24.13. The company has a market cap of $450.24 million, a P/E ratio of -5.65 and a beta of 1.08.

UroGen Pharma (NASDAQ:URGN) last issued its quarterly earnings results on Monday, May 13th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.93) by ($0.04). The business had revenue of $18.78 million during the quarter, compared to analysts’ expectations of $20.73 million. Equities research analysts forecast that UroGen Pharma will post -3.6 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Mark Schoenberg sold 12,000 shares of the stock in a transaction on Monday, March 18th. The stock was sold at an average price of $14.05, for a total value of $168,600.00. Following the transaction, the insider now directly owns 139,437 shares in the company, valued at approximately $1,959,089.85. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 11.13% of the company’s stock.

Institutional Investors Weigh In On UroGen Pharma

A number of institutional investors and hedge funds have recently made changes to their positions in URGN. RA Capital Management L.P. bought a new stake in UroGen Pharma during the 3rd quarter worth approximately $20,787,000. RTW Investments LP grew its holdings in UroGen Pharma by 101.4% during the fourth quarter. RTW Investments LP now owns 1,726,808 shares of the company’s stock worth $25,902,000 after buying an additional 869,344 shares in the last quarter. Silverarc Capital Management LLC purchased a new stake in UroGen Pharma in the 3rd quarter valued at $7,129,000. Price T Rowe Associates Inc. MD bought a new position in UroGen Pharma during the 1st quarter valued at $4,008,000. Finally, Superstring Capital Management LP purchased a new position in UroGen Pharma during the 4th quarter worth $3,831,000. Institutional investors and hedge funds own 91.29% of the company’s stock.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.